Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Oxybutynin
Drug ID BADD_D01643
Description Overactive bladder (OAB) is a common condition negatively impacting the lives of millions of patients worldwide. Due to its urinary symptoms that include nocturia, urgency, and frequency, this condition causes social embarrassment and a poor quality of life.[A185996,A185999] Oxybutynin, also marketed as Ditropan XL, is an anticholinergic medication used for the relief of overactive bladder symptoms that has been optimized for high levels of safety and efficacy since initial FDA approval in 1975.[A183782,L8648] This drug relieves undesirable urinary symptoms, increasing the quality of life for patients affected by OAB. It is often used as first-line therapy for OAB.[A185990]
Indications and Usage For the treatment of overactive bladder.
Marketing Status Prescription; OTC; Discontinued
ATC Code G04BD04
DrugBank ID DB01062
KEGG ID D00465
MeSH ID C005419
PubChem ID 4634
TTD Drug ID D0R1DH
NDC Product Code 68382-257; 50090-5352; 0615-8220; 70771-1088; 70771-1086; 68382-255; 0023-6153; 71335-0974; 68382-256; 70771-1087; 50090-5353; 0615-8219; 17381-015; 0023-9637
Synonyms oxybutynin | 4-(diethylamino)-2-butynyl-alpha-cyclohexyl-alpha-hydroxybenzeneacetate | 4-(diethylamino)-2-butynyl-alpha-phenylcyclohexaneglycolate | Zatur | Contimin | Cystonorm | Ditropan | Dridase | Cystrin | Dresplan | Driptane | gelnique | Gen-Oxybutynin | Novo-Oxybutynin | Nu-Oxybutyn | Oxyb AbZ | Oxybutin Holsten | Oxybuton | Oxybutynin AL | Oxybutynin AZU | Oxybutynin Heumann | Oxybutynin Hexal | oxybutynin hydrochloride | oxybutynin chloride | Oxybutynin Stada | oxybutynin von ct | Oxybutynin-Puren | Oxybutynin-ratiopharm | Oxymedin | Oxytrol | PMS-Oxybutynin | Pollakisu | Renamel | Ryol | Spasmex Oxybutynin | Spasyt | Tavor | Oxybugamma | Apo-Oxybutynin
Chemical Information
Molecular Formula C22H31NO3
CAS Registry Number 5633-20-5
SMILES CCN(CC)CC#CCOC(=O)C(C1CCCCC1)(C2=CC=CC=C2)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Urinary hesitation20.02.02.009--Not Available
Urinary retention20.02.02.0110.000524%
Urinary tract disorder20.08.01.001--Not Available
Urinary tract infection20.08.02.001; 11.01.14.004--
Urticaria10.01.06.001; 23.04.02.0010.000262%
Vision blurred17.17.01.010; 06.02.06.0070.000393%
Visual impairment06.02.06.008--Not Available
Vomiting07.01.07.003--
Application site vesicles23.03.01.009; 12.07.01.009; 08.02.01.009--Not Available
Residual urine volume13.13.03.004--Not Available
Viral diarrhoea11.05.04.012; 07.19.02.008--Not Available
Musculoskeletal discomfort15.03.04.001--Not Available
Depressive symptom19.15.02.003--Not Available
Affect lability19.04.01.001--Not Available
Skin burning sensation23.03.03.021; 17.02.06.0090.000262%Not Available
Paraesthesia oral17.02.06.008; 07.05.03.003--Not Available
Cognitive disorder19.21.02.001; 17.03.03.0030.000262%
Vasodilation procedure25.03.01.001--Not Available
Disturbance in sexual arousal19.08.04.003--Not Available
Angiopathy24.03.02.007--Not Available
Hot flush24.03.01.005; 08.01.03.027; 21.02.02.0010.000262%
Breast disorder21.05.04.004--Not Available
Cardiac disorder02.01.01.003--Not Available
Connective tissue disorder15.06.01.006--Not Available
Infestation23.09.05.001; 11.09.01.001--Not Available
Malnutrition14.03.02.004--Not Available
Mediastinal disorder22.09.03.001--Not Available
Mental disorder19.07.01.002--Not Available
Decreased appetite14.03.01.005; 08.01.09.028--
Erectile dysfunction21.03.01.007; 19.08.04.001--
The 7th Page    First    Pre   7 8    Next   Last    Total 8 Pages